Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prothrombin activation is increased among asymptomatic carriers of the prothrombin G20210A and factor V Arg506Gln mutations.

Thrombosis and haemostasis - 1 Sept 2000

Bauer K A, Humphries S, Smillie B, Li L, Cooper J A, Barzegar S, Rosenberg R D, Miller G J

Abstract excerpt

The risk of venous thrombosis is increased in individuals who carry specific genetic abnormalities in blood coagulation proteins. Among Caucasians, the prothrombin G20210A and factor V Arg506Gln (FV R506Q) mutations are the most prevalent defects identified to date. We evaluated their influence on markers of coagulation activation among participants in the Second Northwick Park Heart Study, which recruited...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Coagulation Factors
Share to Factor V

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Myocardial Infarction

Share to Peptide Fragments

Share to Prothrombin

Share to Thrombophilia

Share to United Kingdom

Share to Venous Thrombosis

Source

Identifiers

PMID: 11019961

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prothrombin activation is increased among asymptomatic carriers of the prothrombin G20210A and factor V Arg506Gln mutations.PMID 11019961Read ↗

Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene.Semantic proximity Read ↗

Prothrombin activity and concentration in healthy subjects with and without the prothrombin G20210A mutation.Semantic proximity Read ↗

Rapid multiplex analysis for the factor V Leiden and prothrombin G20210A mutations associated with hereditary thrombophilia.Semantic proximity Read ↗

Molecular diagnostics in hemostatic disorders.Semantic proximity Read ↗

Prothrombin antigen levels in symptomatic and asymptomatic carriers of the 20210A prothrombin variant.Semantic proximity Read ↗

Differential effects of high prothrombin levels on thrombin generation depending on the cause of the hyperprothrombinemia.Semantic proximity Read ↗

Genetic testing for thrombophilia mutations.Semantic proximity Read ↗

Comparative evaluation of five different methods for the measurement of plasma factor II levels in carriers of the 20210A prothrombin variant.Semantic proximity Read ↗

Prospective study of the G20210A polymorphism in the prothrombin gene, plasma prothrombin concentration, and incidence of venous thromboembolism.Semantic proximity Read ↗

Thrombin generation as an intermediate phenotype for venous thrombosis.Semantic proximity Read ↗

Clinical and laboratory expression of associated thrombophilic conditions (homozygous/heterozygous factor V Leiden mutation and heterozygous prothrombin variant 20210A) in an Italian family.Semantic proximity Read ↗

Prothrombin time, activated partial thromboplastin time and dilute Russell's Viper Venom times are not shorter in patients with the prothrombin G20210A mutation, and dilute Russell's Viper Venom time may be longer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.